Skip to search formSkip to main contentSkip to account menu

tasimelteon

Known as: N-((2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)propanamide, N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide, tasimeltéon 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

BMS 214778Hetlioz

Broader (2)

BenzofuransCyclopropanes
tasimelteon 20 MG Oral Capsule [Hetlioz]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging… 
Review
2016
Review
2016
Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals
Tasimelteon (Hetlioz®) is a dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non… 
Review
2016
Review
2016
Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014
Regulatory approval documents contain valuable information, often not published, to assess the drug–drug interaction (DDI… 
Review
2015
Review
2015
Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
Tasimelteon (Hetlioz®), a melatonin receptor agonist, is the first, and, at the time of the publication, the only drug to be… 
2015
2015
Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies
Introduction: Tasimelteon, a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder… 
Review
2014
Review
2014
Tasimelteon: First Global Approval
Tasimelteon (HETLIOZ™) is an orally bioavailable agonist of the melatonin MT1 and MT2 receptors that has been approved in the US… 
Review
2012
Review
2012
Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.
The CNS is both source and target of melatonin. This methoxyindole formed in the pineal gland is also produced in other CNS… 
Review
2011
Review
2011
Tasimelteon for insomnia
Introduction: Insomnia is a prevalent disorder with nearly 50% of the US adult population reporting insomnia symptoms during the… 
Review
2010
Review
2010
Melatonin agonists and insomnia
The ability of melatonin to shift biological rhythms is well known. As a result, melatonin has been used in the treatment of… 
2009
2009
Health before profits? Learning from Thailand's experience
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)